ATE393229T1 - Tau-opathy modell - Google Patents

Tau-opathy modell

Info

Publication number
ATE393229T1
ATE393229T1 AT02702181T AT02702181T ATE393229T1 AT E393229 T1 ATE393229 T1 AT E393229T1 AT 02702181 T AT02702181 T AT 02702181T AT 02702181 T AT02702181 T AT 02702181T AT E393229 T1 ATE393229 T1 AT E393229T1
Authority
AT
Austria
Prior art keywords
tau
alzheimer
disease
opathy
model
Prior art date
Application number
AT02702181T
Other languages
English (en)
Inventor
Leuven Freddy Van
Joris Winderickx
Original Assignee
Remynd Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9909505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE393229(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Remynd Nv filed Critical Remynd Nv
Application granted granted Critical
Publication of ATE393229T1 publication Critical patent/ATE393229T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02702181T 2001-02-26 2002-02-25 Tau-opathy modell ATE393229T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0104685.3A GB0104685D0 (en) 2001-02-26 2001-02-26 Tau-opathy model

Publications (1)

Publication Number Publication Date
ATE393229T1 true ATE393229T1 (de) 2008-05-15

Family

ID=9909505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02702181T ATE393229T1 (de) 2001-02-26 2002-02-25 Tau-opathy modell

Country Status (8)

Country Link
US (1) US20050009019A1 (de)
EP (1) EP1373529B1 (de)
AT (1) ATE393229T1 (de)
DE (1) DE60226220T2 (de)
DK (1) DK1373529T3 (de)
ES (1) ES2306755T3 (de)
GB (1) GB0104685D0 (de)
WO (1) WO2002068663A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799535B1 (en) 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
US7045290B2 (en) * 2001-02-15 2006-05-16 The University Of Chicago Yeast screens for treatment of human disease
US20050064548A1 (en) * 2003-04-16 2005-03-24 Lindquist Susan L. Yeast ectopically expressing abnormally processed proteins and uses therefor
WO2012162179A1 (en) * 2011-05-20 2012-11-29 Oligomerix, Inc. Tau protease compositions and methods of use
GB201319656D0 (en) 2013-11-07 2013-12-25 Univ Leuven Kath A yeast model for synergistic toxicity
US10865416B2 (en) * 2014-04-17 2020-12-15 Boehringer Ingelheim Rcv Gmbh & Co Kg Recombinant host cell engineered to overexpress helper proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003369A1 (en) * 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
KR940021073A (ko) * 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
WO1994023039A1 (en) * 1993-04-07 1994-10-13 The Institute Of Cancer Research: Royal Cancer Hospital Methods for screening of substances for therapeutic activity and yeast for use therein
GB9316727D0 (en) * 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
US5691137A (en) * 1994-08-30 1997-11-25 Brandeis University Methods of screening candidate agents for biological activity using yeast cells
US5952217A (en) * 1997-09-23 1999-09-14 Bristol-Myers Squibb Company Recombinant yeast cell and assay using same
US7799535B1 (en) * 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
JP2003504015A (ja) * 1999-07-02 2003-02-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 神経変性疾患のモデルとしてのトランスジェニック動物
GB0100119D0 (en) * 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease

Also Published As

Publication number Publication date
ES2306755T3 (es) 2008-11-16
EP1373529B1 (de) 2008-04-23
DK1373529T3 (da) 2008-08-18
WO2002068663A1 (en) 2002-09-06
US20050009019A1 (en) 2005-01-13
DE60226220D1 (de) 2008-06-05
EP1373529A1 (de) 2004-01-02
GB0104685D0 (en) 2001-04-11
DE60226220T2 (de) 2009-08-20

Similar Documents

Publication Publication Date Title
DE602004011770D1 (de) Fusionsproteine
EA200600525A1 (ru) Еро-имитирующие миметичекие антитела человека с центральной шарнирной областью, композиции, способы и применения
ECSP088262A (es) Proteínas de fusión de albúmina
CY1116633T1 (el) Χρηση αναστολεων πεπτιδιου του μονοπατιου μεταγωγης σηματος jnk οι οποιοι διαπερνουν τα κυτταρα για τη θεραπευτικη αγωγη διαφορων καρδιαγγειακων νοσων
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
WO2003086451A8 (en) Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
ATE475432T1 (de) Arzneimittel für herzversagen
BR0215383A (pt) proteases que produzem resposta imunogênica alterada e métodos de fabricação e uso das mesmas
EP1289551A4 (de) HUMANE POLYPEPTIDE WELCHE ZUM ABSTERBEN VON ZELLEN, INSBESONDERE LYMPHOIDER TUMORZELLEN, FüHREN
ATE391781T1 (de) Transgenes tier welches das trunkierte alzheimer tau protein exprimiert
WO2002044320A3 (en) Human elongase genes and uses thereof
WO2004009788A3 (en) Fluorescent proteins, nucleic acids encoding them and methods for making and using them
DE60226220D1 (de) Tau-opathy modell
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
ATE539086T1 (de) Interleukin-11-fusionsproteine
WO2008068428A3 (fr) Utilisation cosmétique de protéines de type chitinase
ATE470716T1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
WO2003082206A3 (en) Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
ATE503834T1 (de) Bibliotheken rekombinanter chimärischer proteine
ATE319739T1 (de) Menschliche wingless-änhliche gene
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
WO2003052377A9 (en) 41 human secreted proteins
ATE512981T1 (de) Identifizierung von ses-3 (spr-5) aus c. elegans sowie dessen verwendungen
DE60237236D1 (de) Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür
ATE364081T1 (de) Identifizierung von ses-1 aus c. elegans sowie dessen verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties